Résumé
Se evaluó la capacidad infectiva de promastigotes de Leishmania amazonensis al ser tratados con una serie de 10 derivados de la tiadiazina. Los parásitos fueron incubados durante 24 h con 1 o 0,1 mg/mL de cada compuesto y posteriormente, se infectaron macrófagos peritoneales de ratones BALB/c en cultivos. Todos los compuestos causaron una reducción de la capacidad infectiva de los parásitos mayor que 50 %. El producto T1O fue el que causó un mayor efecto, disminuyendo la infección en 92,8 % de infección.
The infective capacity of Leishmania amazonensis promastigotes was evaluated after they were treated with a series of 10 thiadiazine derivatives. The parasites were incubated for 24 hours with 1 or 0,1 mg/ml of each compound and then, peritoneal macrophages from BALB/c mice were infected in cultures. All the compounds managed to reduce the infective capacity of parasites by more than 50%. T10 product exhibited the highest effect since it reduced infection by 92,8%.
Résumé
Current therapy for leishmaniasis is not satisfactory. We describe the in vitro antiproliferative effects of new thiadiazine derivatives against Leishmania amazonensis. The compounds were found to be active against the amastigote form of the parasite, inhibiting parasite growing, from 10 to 89 percent, at a concentration of 100 ng/ml. This activity suggests that thiadiazine derivatives could be considered as potential antileishmanial compounds.